MXPA03010099A - Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3. - Google Patents
Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3.Info
- Publication number
- MXPA03010099A MXPA03010099A MXPA03010099A MXPA03010099A MXPA03010099A MX PA03010099 A MXPA03010099 A MX PA03010099A MX PA03010099 A MXPA03010099 A MX PA03010099A MX PA03010099 A MXPA03010099 A MX PA03010099A MX PA03010099 A MXPA03010099 A MX PA03010099A
- Authority
- MX
- Mexico
- Prior art keywords
- vegfr
- diseases
- inhibitors
- disease
- cases
- Prior art date
Links
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title abstract 2
- -1 anthranilamide pyridine amides Chemical class 0.000 title abstract 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037803 restenosis Diseases 0.000 abstract 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 abstract 1
- 208000032544 Cicatrix Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010012442 Dermatitis contact Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 208000017604 Hodgkin disease Diseases 0.000 abstract 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 abstract 1
- 208000007766 Kaposi sarcoma Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000010247 contact dermatitis Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 201000011066 hemangioma Diseases 0.000 abstract 1
- 206010020718 hyperplasia Diseases 0.000 abstract 1
- 230000002390 hyperplastic effect Effects 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000035168 lymphangiogenesis Effects 0.000 abstract 1
- 210000004324 lymphatic system Anatomy 0.000 abstract 1
- 210000003584 mesangial cell Anatomy 0.000 abstract 1
- 201000003142 neovascular glaucoma Diseases 0.000 abstract 1
- 201000009925 nephrosclerosis Diseases 0.000 abstract 1
- 210000000944 nerve tissue Anatomy 0.000 abstract 1
- 230000002085 persistent effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 231100000241 scar Toxicity 0.000 abstract 1
- 230000037387 scars Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2001123574 DE10123574A1 (de) | 2001-05-08 | 2001-05-08 | Selektive Anthranylamid-Derivate als VEGFR II Inhibitoren |
| DE2001125294 DE10125294A1 (de) | 2001-05-15 | 2001-05-15 | Selektive Anthranylamid-Derivate als VEGFR-2 und VEGFR-3 Inhibitoren |
| DE2001164590 DE10164590A1 (de) | 2001-12-21 | 2001-12-21 | Anthranylamidpyridinamide als VEGFR-2 und VEGFR-3 Inhibitoren |
| PCT/EP2002/004924 WO2002090352A2 (de) | 2001-05-08 | 2002-05-03 | Selektive anthranylamidpyridinamide als vegfr-2 und vegfr-3 inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03010099A true MXPA03010099A (es) | 2004-03-10 |
Family
ID=27214428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03010099A MXPA03010099A (es) | 2001-05-08 | 2002-05-03 | Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20040254185A1 (enExample) |
| EP (1) | EP1392680B1 (enExample) |
| JP (1) | JP2004528379A (enExample) |
| KR (1) | KR20030094395A (enExample) |
| CN (1) | CN1518546A (enExample) |
| BR (1) | BR0209485A (enExample) |
| CA (1) | CA2453223A1 (enExample) |
| DE (1) | DE50213703D1 (enExample) |
| IL (1) | IL158783A0 (enExample) |
| MX (1) | MXPA03010099A (enExample) |
| NO (1) | NO20034957D0 (enExample) |
| PE (1) | PE20021092A1 (enExample) |
| PL (1) | PL364478A1 (enExample) |
| WO (1) | WO2002090352A2 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US20030134836A1 (en) * | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| WO2004013102A1 (de) * | 2002-07-31 | 2004-02-12 | Schering Aktiengesellschaft | Vegfr-2 und vegfr-3 inhibitorische anthranylamidpyrimidene |
| GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
| EP1628661A2 (en) * | 2003-06-05 | 2006-03-01 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
| DE10327719A1 (de) * | 2003-06-13 | 2005-01-20 | Schering Ag | VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone |
| US7202260B2 (en) * | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
| US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| DE102004009238A1 (de) * | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
| CN1660811A (zh) * | 2004-02-27 | 2005-08-31 | 中国科学院上海药物研究所 | 1，4－二取代苯类化合物及其制备方法和用途 |
| US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| KR20060071812A (ko) * | 2004-12-22 | 2006-06-27 | 주식회사 엘지생명과학 | 신규한 3-(2-아미노-6-피리디닐)-4-히드록시페닐 아민유도체 |
| WO2006070878A1 (ja) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | カルボン酸誘導体またはその塩 |
| WO2006078621A2 (en) | 2005-01-19 | 2006-07-27 | Bristol-Myers Squibb Company | 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders |
| JP4585978B2 (ja) * | 2005-03-03 | 2010-11-24 | 参天製薬株式会社 | キノリルアルキルチオ基を有する新規環式化合物 |
| DE602006017694D1 (de) | 2005-06-27 | 2010-12-02 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden |
| TW200726764A (en) | 2005-06-27 | 2007-07-16 | Bristol Myers Squibb Co | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| WO2007002634A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| ATE502924T1 (de) | 2005-06-27 | 2011-04-15 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden |
| US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| CA2629964A1 (en) * | 2005-11-30 | 2007-06-07 | Astellas Pharma Inc. | 2-aminobenzamide derivative |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| PE20081636A1 (es) * | 2007-01-26 | 2009-01-10 | Smithkline Beecham Corp | Inhibidores de antranilamida para aurora quinasa |
| FR2917413B1 (fr) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique |
| RU2522444C2 (ru) | 2008-08-27 | 2014-07-10 | Лео Фарма А/С | Производные пиридина в качестве ингибиторов рецепторов фактора роста эндотелия сосудов 2 подтипа (vegfr-2) и протеинтирозинкиназы |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| AU2010289353B2 (en) * | 2009-09-03 | 2016-12-08 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| KR101524923B1 (ko) * | 2013-08-02 | 2015-06-01 | 가톨릭대학교 산학협력단 | ＩＦＮ－γ의 발현을 증가시키는 ＶＥＧＦＲ－３ 억제제를 유효성분으로 포함하는 급성골수성백혈병 치료용 약학적 조성물 |
| CN104163794A (zh) * | 2013-10-17 | 2014-11-26 | 中国药科大学 | 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途 |
| CN106496107A (zh) * | 2016-08-31 | 2017-03-15 | 浙江永宁药业股份有限公司 | Vegfr‑2抑制剂及其制备方法 |
| CN108467360B (zh) * | 2018-06-22 | 2021-04-30 | 江苏美迪克化学品有限公司 | 一种阿帕替尼的制备方法及其中间体 |
| US20210179543A1 (en) * | 2018-08-13 | 2021-06-17 | Western University Of Health Sciences | Calpain-2 selective inhibitor compounds for treatment of glaucoma |
| KR102371269B1 (ko) * | 2020-03-11 | 2022-03-07 | 연세대학교 산학협력단 | VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법 |
| CN117603175B (zh) * | 2023-11-27 | 2024-08-06 | 南开大学 | 一种苯并吡喃结构的查尔酮类衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716993A (en) * | 1993-12-27 | 1998-02-10 | Eisai Co., Ltd. | Anthranilic acid derivatives |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| DE10023492A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
| JP4343681B2 (ja) * | 2001-05-08 | 2009-10-14 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | シアノアントラニルアミド誘導体およびそれらの薬剤としての使用 |
| US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
-
2002
- 2002-05-03 WO PCT/EP2002/004924 patent/WO2002090352A2/de not_active Ceased
- 2002-05-03 CN CNA028095804A patent/CN1518546A/zh active Pending
- 2002-05-03 PL PL02364478A patent/PL364478A1/xx unknown
- 2002-05-03 DE DE50213703T patent/DE50213703D1/de not_active Expired - Fee Related
- 2002-05-03 BR BR0209485-1A patent/BR0209485A/pt not_active IP Right Cessation
- 2002-05-03 CA CA002453223A patent/CA2453223A1/en not_active Abandoned
- 2002-05-03 MX MXPA03010099A patent/MXPA03010099A/es active IP Right Grant
- 2002-05-03 US US10/477,119 patent/US20040254185A1/en not_active Abandoned
- 2002-05-03 JP JP2002587431A patent/JP2004528379A/ja active Pending
- 2002-05-03 EP EP02735333A patent/EP1392680B1/de not_active Expired - Lifetime
- 2002-05-03 IL IL15878302A patent/IL158783A0/xx unknown
- 2002-05-03 KR KR10-2003-7014539A patent/KR20030094395A/ko not_active Ceased
- 2002-05-08 PE PE2002000384A patent/PE20021092A1/es not_active Application Discontinuation
-
2003
- 2003-11-07 NO NO20034957A patent/NO20034957D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL364478A1 (en) | 2004-12-13 |
| NO20034957D0 (no) | 2003-11-07 |
| EP1392680A2 (de) | 2004-03-03 |
| CA2453223A1 (en) | 2002-11-14 |
| PE20021092A1 (es) | 2003-01-11 |
| US20040254185A1 (en) | 2004-12-16 |
| IL158783A0 (en) | 2004-05-12 |
| DE50213703D1 (de) | 2009-09-03 |
| KR20030094395A (ko) | 2003-12-11 |
| CN1518546A (zh) | 2004-08-04 |
| JP2004528379A (ja) | 2004-09-16 |
| WO2002090352A2 (de) | 2002-11-14 |
| EP1392680B1 (de) | 2009-07-22 |
| WO2002090352A3 (de) | 2003-05-01 |
| BR0209485A (pt) | 2004-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03010099A (es) | Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3. | |
| BR0313122A (pt) | Antranilamidopiridinas inibidoras de vegfr-2 e vegfr-3 | |
| CY1105140T1 (el) | Παραγωγα κυανοανθρανυλαμιδιου και η χρηση τους ως φαρμακευτικα μεσα | |
| JP2004528379A5 (enExample) | ||
| Kao et al. | Minimally invasive surgery: video endoscopic thoracic sympathectomy for palmar hyperhidrosis. | |
| Binkert et al. | Retrievability of the recovery vena cava filter after dwell times longer than 180 days | |
| AR035877A1 (es) | Derivados de n-oxido-antranilamida, su uso para preparar un medicamento y los medicamentos que los contienen | |
| Shi et al. | The effect of endovenous laser ablation of incompetent perforating veins and the great saphenous vein in patients with primary venous disease | |
| MX2009012126A (es) | 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil-pirazinas y piridinas y 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas del receptor 5-ht7. | |
| YU2704A (sh) | 2- (3, 5-BIS-TRIFLUORMETIL-FENIL) -N-[6-(1, 1-DIOKSO-1λ6-TI0M0RF0LIN-4-IL)-4-(2-METIL- ILI 4-FLUOR-2-METIL- SUPSTITUISAN) -FENIL-PIRIDIN-3-IL]-N-METIL-IZOBUTIRAMID | |
| Ter Bekke et al. | Visual bodily signals and conversational context benefit the anticipation of turn ends | |
| Hewitt et al. | Flexion vs. extension: a comparison of post-operative total knee arthroplasty mobilisation regimes | |
| Guo et al. | Diplopia and strabismus following ocular surgeries | |
| CN102415930A (zh) | 智能理疗床 | |
| CN208114733U (zh) | 一种狂躁病人用病床 | |
| Cioroiu | Function of the Upper Member in Stroke | |
| Salem et al. | EP62 Endovascular transcarotid artery revascularization using the walrus balloon guide catheter: safety and feasibility from multicenter experience | |
| Chan et al. | EP61 Direct carotid puncture for mechanical thrombectomy in acute ischaemic stroke: a single centre experience and review of the literature | |
| RU2515756C1 (ru) | Способ лечения пролежней у больных с ортопедической патологией в ходе ее устранения с применением аппаратов внешней фиксации | |
| CN102415940A (zh) | 理疗床 | |
| Troisi et al. | Safety and effectiveness of the Phoenix atherectomy device for endovascular treatment of common femoral and popliteal arteries: Results of the EN-MOBILE trial | |
| Koehler et al. | Axillary web syndrome | |
| AR035878A1 (es) | Antranilamidopiridinamidas selectivas, su uso para preparar un medicamento y los medicamentos que las contienen | |
| PT3907317T (pt) | Dispositivo e processo para o tratamento a laser de calças que compreende dois manequins | |
| ZHANG et al. | Endovascular treatment for closed articular artery injuries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |